The role of risk communication in the care of osteoporosis

Current Osteoporosis Reports

Volumn 9, Issue 3, 2011, Pages 141-148

  Lewiecki, E Michael ^a  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

Author keywords

Benefit; Drugs; Fracture; Osteoporosis; Risk; Risk communication; Treatment

Indexed keywords

PLACEBO; ZOLEDRONIC ACID;

ARTICLE; CLINICAL EFFECTIVENESS; COMMUNICATION SKILL; DOCTOR PATIENT RELATION; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; INFORMATION DISSEMINATION; MEDICAL DECISION MAKING; OSTEOPOROSIS; PATIENT ATTITUDE; PATIENT CARE; PATIENT DECISION MAKING; PATIENT EDUCATION; PATIENT INFORMATION; PHYSICIAN ATTITUDE; RISK ASSESSMENT; TREATMENT PLANNING;

EID: 85027929811     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-011-0056-1     Document Type: Article

References (50)

1. World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: WHO; 1994.
2. Curtis JR, Carbone L, Cheng H, et al. Longitudinal trends in use of bone mass measurement among older Americans, 1999-2005. J Bone Miner Res. 2008;23(7):1061-7. (Pubitemid 351915728)
3. Foley KA, Foster SA, Meadows ES, et al. Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure. Med Care. 2007;45(9):902-6.
4. McCombs JS, Thiebaud P, Laughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48(3):271-87. (Pubitemid 38781153)
5. Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int. 2003;14(12): 965-8. (Pubitemid 40824268)
6. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15(12):1003-8. (Pubitemid 40064656)
7. Nguyen ND, Frost SA, Center JR, et al. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int. 2008;19(10):1431-44.
8. Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ. 2009;339: b4229.
9. Kanis JA, on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases. UK: University of Sheffield. Printed by the University of Sheffield; 2007.
10. Leslie WD, Tsang JF, Lix LM. Simplified system for absolute fracture risk assessment: clinical validation in Canadian women. J Bone Miner Res. 2009;24(2):353-60.
11. Kanis JA, Johansson H, Oden A, McCloskey EV. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX((R)). Bone. 2009;44:1049-54.
12. McCloskey EV, Johansson H, Oden A, et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy-additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int. 2009;20(5):811-7.
13. Lewiecki EM. Fracture risk assessment in clinical practice: Tscores, FRAX, and beyond. Clinic Rev Bone Miner Metab. 2009;8(3):101-12.
14. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-22. (Pubitemid 46698462)
15. US Food and Drug Administration. Update of safety review followup to the October 1, 2007. Early communication about the ongoing safety review of bisphosphonates. Available at http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm. Accessed March 2010.
16. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479-89.
17. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267-94.
18. Epictetus: Epictetus. Available at http://www.brainyquote.com/quotes/ quotes/e/epictetus149127.html. Accessed April 2010.
19. Radonich M. Communicating radiation risk to the public. Available at http://www.cemp.dri.edu/cemp/workshop2006/presentations/Radonich-Communicating- Radiation-Risk-to-the-Public-Part-1.pdf. Accessed January 2011.
20. Sandman PM. Crisis communication (high hazard, high outrage). Available at http://www.psandman.com/index-CC.htm. Accessed January 2011.
21. Rossini M, Bianchi G, Di MO, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 2006;17(6):914-21. (Pubitemid 43781506)
22. Covello VT, Sandman PM. Risk communication: evolution and revolution. Available at http://www.psandman.com/articles/covello. htm. Accessed April 2010.
23. Lewiecki EM, Binkley N. Evidence-based medicine, clinical practice guidelines, and common sense in the management of osteoporosis. Endocr Pract. 2009;24(10):1643-6.
24. Panneman MJ, Lips P, Sen SS, Herings RM. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int. 2004;15(2):120-4. (Pubitemid 38252425)
25. Giangregorio L, Dolovich L, Cranney A, et al. Osteoporosis risk perceptions among patients who have sustained a fragility fracture. Patient Educ Couns. 2009;74(2):213-20. This study shows that patients commonly underestimate the risk of future fracture following a fracture and thereby be less likely to be motivated to be treated to reduce fracture risk.
26. Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med. 2006;119(4 Suppl 1):S12-7.
27. Edwards A, Elwyn G. How should effectiveness of risk communication to aid patients' decisions be judged? A review of the literature. Med Decis Mak. 1999;19(4):428-34. (Pubitemid 29474769)
28. Rothman AJ, Kiviniemi MT. Treating people with information: an analysis and review of approaches to communicating health risk information. J Natl Cancer Inst Monogr. 1999;25:44-51.
29. Waitzkin H. Doctor-patient communication. Clinical implications of social scientific research. JAMA. 1984;252(17):2441-6. (Pubitemid 14021854)
30. Braddock III CH, Edwards KA, Hasenberg NM, et al. Informed decision making in outpatient practice: time to get back to basics. JAMA. 1999;282(24):2313-20. (Pubitemid 30013062)
31. Whitney SN. A new model of medical decisions: exploring the limits of shared decision making. Med Decis Mak. 2003;23 (4):275-80. (Pubitemid 36899093)
32. Lloyd AJ, Hayes PD, London NJ, et al. Patients' ability to recall risk associated with treatment options. Lancet. 1999;353 (9153):645 [Research Letter]. (Pubitemid 29087992)
33. Schwartz LM, Woloshin S, Black WC, Welch HG. The role of numeracy in understanding the benefit of screening mammography. Ann Intern Med. 1997;127(11):966-72. (Pubitemid 27516607)
34. Lipkus IM, Samsa G, Rimer BK. General performance on a numeracy scale among highly educated samples. Med Decis Mak. 2001;21(1):37-44. (Pubitemid 32245029)
35. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360(1):89-90.
36. Galesic M, Garcia-Retamero R, Gigerenzer G. Using icon arrays to communicate medical risks: overcoming low numeracy. Health Psychol. 2009;28(2):210-6. This is a thought-provoking study of the challenges in communicating risk to patients and methods to enhance better understanding of risk.
37. Gaissmaier W, Gigerenzer G. Statistical illiteracy undermines informed shared decision making. Z Evid Fortbild Qual Gesundhwes. 2008;102(7):411-3.
38. Sambrook PN, Chen JS, Simpson JM, March LM. Impact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortality. Med J Aust. 2010;193(3):154-6. This is a case study of the harm to patients that may be the result of inaccurate and misleading news reporting of possible adverse effects of pharmacologic therapy for osteoporosis.
39. O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2009;(3):CD001431.
40. Meyer G, Steckelberg A, Muhlhauser I. Analysis of consumer information brochures on osteoporosis prevention and treatment. Ger Med Sci. 2007;5:1-9.
41. Lewiecki EM, Rudolph LA, Kiebzak GM, et al. Assessment of osteoporosis-website quality. Osteoporos Int. 2006;17(5):741-52.
42. Ancker JS, Senathirajah Y, Kukafka R, Starren JB. Design features of graphs in health risk communication: a systematic review. J Am Med Inform Assoc. 2006;13(6):608-18. (Pubitemid 44649360)
43. Schapira MM, Nattinger AB, McHorney CA. Frequency or probability? A qualitative study of risk communication formats used in health care. Med Decis Mak. 2001;21(6):459-67. (Pubitemid 33070851)
44. Lewiecki EM. Risk communication and shared decision making in the care of patients with osteoporosis. J Clin Densitom. 2010;13 (4):335-45.
45. Boudreau JD, Cassell E, Fuks A. Preparing medical students to become attentive listeners. Med Teach. 2009;31(1):22-9.
46. Winzenberg T, Oldenburg B, Frendin S, et al. The effect on behavior and bone mineral density of individualized bone mineral density feedback and educational interventions in premenopausal women: a randomized controlled trial [NCT00273260]. BMC Public Health. 2006;6:1-12.
47. Silverman SL, Greenwald M, Klein RA, Drinkwater BL. Effect of bone density information on decisions about hormone replacement therapy: a randomized trial. Obstet Gynecol. 1997;89:321-5. (Pubitemid 27090343)
48. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89(3):1117-23. (Pubitemid 38368399)
49. Briot K, Ravaud P, Dargent-Molina P, et al. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int. 2009;20(4):625-30.
50. Pencille LJ, Campbell ME, Van Houten HK, et al. Protocol for the osteoporosis choice trial. A pilot randomized trial of a decision aid in primary care practice. Trials. 2009;10:1-9.